With the recent FDA approval of the first siRNA‐derived therapeutic, RNA interference
(RNAi)‐mediated gene therapy is undergoing a transition from research to the clinical …

MicroRNAs (miRNAs) represent a family of short non-coding regulatory RNA molecules that
are produced in a tissue and time-specific manner to orchestrate gene expression post …

The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …

Biological drugs are attracting tremendous attention in disease treatment. However, their
application is significantly limited by their inherent properties, such as high hydrophilicity …

The liposome, a closed phospholipid bilayered vesicular system, has received considerable
attention as a pharmaceutical carrier of great potential over the past 30 years. The ability of …

Marketed therapies in the pharmaceutical landscape are rapidly evolving and getting more
diverse. Small molecule medicines have dominated in the past while antibodies have grown …

The selective delivery of drugs in a cell-or tissue-specific manner represents the main
challenge for medical research; in order to reduce the occurrence of unwanted off-target …

In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in
gene therapy has had a great impact in the medical field, holding enormous promise …

Non-coding RNAs (ncRNAs) like microRNAs (miRNAs) or small interference RNAs (siRNAs)
with their power to selectively silence any gene of interest enable the targeting of so far …

Nucleic acid therapeutics, including siRNAs, miRNAs/antimiRs, gRNAs and ASO, represent
innovative and highly promising molecules for the safe treatment of a wide range of …